期刊
CANCER SCIENCE
卷 104, 期 7, 页码 965-976出版社
WILEY
DOI: 10.1111/cas.12203
关键词
-
类别
资金
- Mitsubishi Tanabe Pharma Corporation
- Takeda Pharmaceutical Company
- MSD
- Novo Nordisk Pharma Ltd
- Daiichi Sankyo Inc
- Sanofi
- Takeda
- Boehringer
- Eli Lilly and Company
- Novartis Pharmaceutical Company
- Astellas Pharma Inc.
- Dainippon Sumitomo Pharma
- Daiichi Sankyo
- Chugai Pharmaceutical Company
- Daiichi Sankyo Inc.
In recent years, diabetes has been shown to be associated with cancer risk, and this has led to a joint committee being formed, enlisting experts from the Japan Diabetes Society and the Japanese Cancer Association to address this issue. Epidemiological data in Japan provides evidence to demonstrate that diabetes is associated with increased risk for cancers, especially colorectal, liver, and pancreatic cancers. The mechanisms through which diabetes is assumed to promote oncogenesis include insulin resistance and associated hyperinsulinemia, hyperglycemia, and inflammation. Common risk factors for type 2 diabetes and cancer include aging, male sex, obesity, physical inactivity, inappropriate diet (excessive red/processed meat intake, inadequate vegetable/fruit/dietary fiber intake), excessive alcohol drinking, and smoking. Given that inappropriate diet/exercise, smoking and excessive alcohol drinking are common risk factors for diabetes and cancer, diet/exercise therapy, smoking cessation and alcohol moderation may be associated with decreased risk for cancer in diabetic patients. There is as yet limited evidence as to whether any particular antidiabetic agents may influence cancer risk.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据